Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).
The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.
Nuvoco Vistas Corporation Ltd, Cipla Ltd, Aadhar Housing Finance Ltd, Alkem Laboratories Ltd are among the other stocks to see a surge in volumes on BSE today, 14 July 2026.
Biocon Ltd saw volume of 473.28 lakh shares by 10:46 IST on BSE, a 224.63 fold spurt over two-week average daily volume of 2.11 lakh shares. The stock increased 7.08% to Rs.439.60. Volumes stood at 5.05 lakh shares in the last session.
Nuvoco Vistas Corporation Ltd clocked volume of 8.72 lakh shares by 10:46 IST on BSE, a 56.34 times surge over two-week average daily volume of 15478 shares. The stock gained 7.81% to Rs.340.35. Volumes stood at 39713 shares in the last session.
Cipla Ltd notched up volume of 8.18 lakh shares by 10:46 IST on BSE, a 17.21 fold spurt over two-week average daily volume of 47526 shares. The stock rose 1.42% to Rs.1,447.00. Volumes stood at 20923 shares in the last session.
Aadhar Housing Finance Ltd notched up volume of 7.5 lakh shares by 10:46 IST on BSE, a 5.79 fold spurt over two-week average daily volume of 1.30 lakh shares. The stock slipped 2.50% to Rs.522.40. Volumes stood at 7.09 lakh shares in the last session.
Alkem Laboratories Ltd notched up volume of 1.9 lakh shares by 10:46 IST on BSE, a 5.3 fold spurt over two-week average daily volume of 35790 shares. The stock slipped 0.28% to Rs.5,559.15. Volumes stood at 39767 shares in the last session.
Cipla Ltd gained for a fifth straight session today. The stock is quoting at Rs 1476.6, up 2.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.46% on the day, quoting at 23944.45. The Sensex is at 76716.34, down 0.5%. Cipla Ltd has risen around 6.21% in last one month.
Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 4.4% in last one month and is currently quoting at 24969.5, up 1.25% on the day. The volume in the stock stood at 20.59 lakh shares today, compared to the daily average of 15.8 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1472.9, up 2.22% on the day. Cipla Ltd is down 1.95% in last one year as compared to a 6.16% drop in NIFTY and a 14.71% drop in the Nifty Pharma index.
The PE of the stock is 33.8 based on TTM earnings ending March 26.
The brokerage expects a series of near-term developments to support the stock. These include the anticipated approval of gFlovent from Cipla's Goa facility and the planned launch of gVentolin, both of which could strengthen the company's position in the US market.
The brokerage also highlighted the strong performance of Nintedanib in the US, where the product has captured nearly half of the market. It expects Cipla's US business to return to growth after a period of weakness.
The brokerage said the company's India business remains resilient, supported by a recovery in its respiratory portfolio. It added that a re-inspection of Cipla's Indore manufacturing facility is expected shortly, and a favourable outcome along with USFDA clearance could act as an additional trigger for the stock.
The brokerage further noted that easing geopolitical tensions have reduced concerns over raw material costs and margin pressures.
According to the report, the earnings impact from the decline in gRevlimid-related sales has largely played out, suggesting that Cipla's profit cycle may have bottomed out. The stock is currently valued at around 25 times FY27 estimated earnings and 21 times FY28 estimated earnings.
The brokerage said Cipla offers a compelling combination of domestic pharmaceutical exposure, improving US business prospects and attractive valuations. It noted that the company's India business is valued at 7.8 times FY26 sales, compared with 8.5 times for peer Mankind Pharma, making the risk-reward profile favourable.
Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.
The drug major's consolidated net profit stood at Rs 554.64 crore in Q4 FY26, down 54.61% from Rs 1,221.84 crore in Q4 FY25. Revenue from operations declined 2.02% YoY to Rs 6,464.26 crore in Q4 FY26 from Rs 6,597.72 crore in the year-ago period.
Puri, who currently serves as managing director (MD) and chief executive officer (CEO) of Cipla Health, a wholly owned subsidiary of Cipla, will also be designated as a Senior Management Personnel of the company.
The appointment is on a full-time employment basis, Cipla said in a regulatory filing.
Puri has been leading Cipla Health since 2019 and has played a key role in expanding its consumer healthcare and wellness portfolio across categories such as smoking cessation, pain care, cough and cold, skincare, haircare and nutrition. Under his leadership, the business evolved from a startup venture into one of India's leading wellness-focused consumer goods companies.
He brings more than 23 years of leadership experience across the FMCG and healthcare sectors. Before joining Cipla Health, Puri held senior leadership positions at Hindustan Unilever Ltd, Jubilant FoodWorks Ltd and ITC Ltd.
During his tenure at Hindustan Unilever, he managed multiple businesses, including the Pureit water purifier portfolio, homecare division and modern trade operations, besides overseeing brands such as Surf Excel.
Puri holds a Bachelor of Technology degree from IIT (BHU) Varanasi and an MBA from the Indian Institute of Management (IIM), Lucknow.
Shares of Cipla shed 0.63% to end at Rs 1,372.75 on the BSE.
The counter rose 0.61% to Rs 1384.65 on the BSE.